TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02619981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restorative procedure
Description: A restorative dental procedure requiring maxillary buccal infiltration anesthesia, and not exceeding 30 minutes of working time

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restorative procedure
Description: A restorative dental procedure requiring maxillary buccal infiltration anesthesia, and not exceeding 30 minutes of working time

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restorative procedure
Description: A restorative dental procedure requiring maxillary buccal infiltration anesthesia, and not exceeding 30 minutes of working time
Study: NCT02455791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Biopsy
Description: Ultrasound-guided biopsy of tumor site. A needle is inserted into the affected area using an ultrasound to collect cells or tissue from a tumor mass. Two (2) types of samples collected.
Study: NCT01429675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bonviva
Description: 150mg Ibandronate once a month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bonviva
Description: 150mg Ibandronate once a month
Study: NCT04151212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT5906 injection
Description: Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection
Study: NCT03186209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab subcutaneously on study week 0 until study week 40 inclusive.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously on study week 0 until study week 40 inclusive.
Study: NCT03889184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitating meals-on-wheels service
Description: the meals-on-wheels service will be specifically targeted for old people discharged from hospital, receiving exercise rehabilitation in the municipality or already receiving meals-on-wheels
Study: NCT00971659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine + exenatide + preexisting metformin
Description: insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, exenatide 5ug twice daily subcutaneously for 2 weeks, then 10ug twice daily for 2 weeks, continuation of preexisting metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine + sitagliptin + preexisting metformin
Description: insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, sitagliptin 100 mg once daily in the morning over 4 weeks, continuation of preexisting metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine + preexisting metformin
Description: insulin glargine once daily subcutaneously over 4 weeks, continuation of preexisting metformin
Study: NCT04205240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO or IV
Study: NCT01810471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Applying ankle support device (white non-elastic tape, kinesiotape (TM), soft brace (Malleotrain TM)
Study: NCT03314103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One shot of the varicella-zoster virus vaccine
Description: One shot of the live attenuated varicella-zoster virus vaccine (with live virus \>=4.3 LgPFU per dose)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: one shot of placebo
Description: one shot of placebo with no live virus
Study: NCT01660971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT04268641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1
Description: Materials used for the course :~1. : Standard Wheelchair~2. : Standard Wheelchair + Seat back + Positioning cushion~3. : Standard Wheelchair + Seat back + Positioning cushion + Belt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 2
Description: Materials used for the course :~1. : Standard Wheelchair~2. : Standard Wheelchair + Seat back + Positioning cushion + Belt~3. : Standard Wheelchair + Seat back + Positioning cushion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 3
Description: Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion~2. : Standard Wheelchair + Seat back + Positioning cushion + Belt~3. : Standard Wheelchair

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 4
Description: Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion~2. : Standard Wheelchair~3. : Standard Wheelchair + Seat back + Positioning cushion + Belt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 5
Description: Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion + Belt~2. : Standard Wheelchair~3. : Standard Wheelchair + Seat back + Positioning cushion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 6
Description: Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion + Belt~2. : Standard Wheelchair + Seat back + Positioning cushion~3. : Standard Wheelchair
Study: NCT02366494

Intervention type: DRUG
Intervention: Bicalutamide
Description: ANDROGEN BLOCKADE

Intervention type: DRUG
Intervention: Bicalutamide
Description: ANDROGEN BLOCKADE

Intervention type: DRUG
Intervention: Leuprolide
Description: ANDROGEN BLOCKADE

Intervention type: DRUG
Intervention: Leuprolide
Description: ANDROGEN BLOCKADE

Intervention type: DRUG
Intervention: Goserelin
Description: ANDROGEN BLOCKADE

Intervention type: DRUG
Intervention: Goserelin
Description: ANDROGEN BLOCKADE

Intervention type: DRUG
Intervention: Triptorelin
Description: ANDROGEN BLOCKADE

Intervention type: DRUG
Intervention: Triptorelin
Description: ANDROGEN BLOCKADE

Intervention type: DRUG
Intervention: Docetaxel
Description: Chemo hormonal therapy

Intervention type: DRUG
Intervention: Abiraterone
Description: Chemo hormonal therapy

Intervention type: DRUG
Intervention: Apalutamide
Description: Nonsteroidal antiandrogen medication

Intervention type: DRUG
Intervention: Enzalutamide
Description: Nonsteroidal antiandrogen medication
Study: NCT04390880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: Study participants will receive intravenous administration of 18F-DCFPyL and undergo a PET/CT imaging study. Patients may be reenrolled in the study, if 18F-DCFPyL PET/CT is performed for subsequent management decision.
Study: NCT03796559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magseed Marker
Description: Implantable Magseed marker for marking lesions in soft tissue, detected using the Sentimag handheld probe.
Study: NCT01346358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-CS4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-CS4
Study: NCT02511665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Given metformin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-MRI Scan
Description: Patients will under go 2 PET-MRI scans in the PET-MRI substudy arm one before treatment with metformin and one after

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given placebo
Study: NCT03484130

Intervention type: DIETARY_SUPPLEMENT
Intervention: Sodium loaded diet
Description: At baseline, and annually, participants will undergo aldosterone dynamic testing after \~5 days of a sodium loaded diet. The diet will consist of \>180 mmol/day of sodium, \~50 mmol/day of potassium, and 600mg/d of calcium.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Restricted sodium diet
Description: At baseline, and annually, participants will undergo aldosterone dynamic testing after \~5 days of a sodium restricted diet. The diet will consist of \<40 mmol/day of sodium, \~50 mmol/day of potassium, and 600mg/d of calcium.
Study: NCT02619981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary infiltration anesthesia with 2%Lidocaine
Description: 1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle
Study: NCT04405791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active stimulation group Sham stimluation group
Description: Participants are randomly assigned to either treatment group or sham group for application of transcranial low intensity focused ultrasound stimulation. For sham group, transducer is surrounded by rubber band in order to block the transmission of ultrasonic wave.~Before initiating transcranial low intensity focused ultrasonic stimulation, in order to identify anatomical structure of the brain, Brain Magnetic Resonance Image(MRI) and Computer Tomography(CT) will be taken. For image coordination, multi-modal stick(fiducial marker, PinPoint) will be attached to the participant.~With acquired brain images of the participant, researchers identify participant's dorsolateral prefrontal cortex(DLPFC) region, and design focused ultrasound focus targeting, image-guidance method.~The treatment is started by targeting left DLPFC region according to assigned groups. Both the treatment and sham group will be under procedure for 2 weeks, 3 times a week.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Active stimulation group Sham stimluation group
Description: Participants are randomly assigned to either treatment group or sham group for application of transcranial low intensity focused ultrasound stimulation. For sham group, transducer is surrounded by rubber band in order to block the transmission of ultrasonic wave.~Before initiating transcranial low intensity focused ultrasonic stimulation, in order to identify anatomical structure of the brain, Brain Magnetic Resonance Image(MRI) and Computer Tomography(CT) will be taken. For image coordination, multi-modal stick(fiducial marker, PinPoint) will be attached to the participant.~With acquired brain images of the participant, researchers identify participant's dorsolateral prefrontal cortex(DLPFC) region, and design focused ultrasound focus targeting, image-guidance method.~The treatment is started by targeting left DLPFC region according to assigned groups. Both the treatment and sham group will be under procedure for 2 weeks, 3 times a week.
Study: NCT00688896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-705 600 mg and pravastatin 40 mg
Description: * JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-705 300 mg and pravastatin 40 mg
Description: * JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment~* Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and pravastatin 40 mg
Description: * Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
Study: NCT03253796

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab
Description: Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of matching placebo for golimumab.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injections of matching placebo for golimumab.
Study: NCT02516696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 500mg PO twice daily on days 1-28 for a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
Study: NCT02619981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary infiltration anesthesia with 2%Lidocaine
Description: 1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary infiltration anesthesia with 2%Lidocaine
Description: 1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle
Study: NCT02516696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
Study: NCT04094597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: lactoferrin is given orally in comparsion to placebp

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebp is given in 2 ml saline
Study: NCT03651700

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TMS
Description: Active TMS will be at 90% motor threshold
Study: NCT00986973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin
Description: All subjects will receive 20 mg/kg/day Sapropterin (KUVAN) for four months. Subjects will be examined with fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging, physical and neurological exam, blood tests for phenylalanine (Phe) and tyrosine levels, and neuropsychological testing before and 4 months after KUVAN therapy. Subjects Phe and tyrosine levels will be monitored weekly during the study and subjects will keep 3-day diet records to allow for calculation of Phe intake.
Study: NCT03651700

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham TMS will be administered

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CILT
Description: 60-90 minutes of CILT will be administered during each treatment session

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CILT
Description: 60-90 minutes of CILT will be administered during each treatment session
Study: NCT01861808

Intervention type: OTHER
Group type: OTHER
Intervention: Lumbar puncture
Description: The only intervention is the lumbar puncture on the patients to obtain a Cerebrospinal Fluid sample
Study: NCT04643808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagus nerve stimulation
Description: Microcurrent stimulation delivered to the left tragus, with stimulation 'on' during sucking from a bottle, and 'off' at rest during bottle feeding

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagus nerve stimulation
Description: Microcurrent stimulation delivered to the left tragus, with stimulation 'on' during sucking from a bottle, and 'off' at rest during bottle feeding
Study: NCT01593826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Charcoal and Budesonide/formoterol Easyhaler 320/9 microg
Description: 2 inhalations as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Charcoal and Symbicort Turbuhaler
Description: 2 inhalations as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol Easyhaler 320/9 microg
Description: 2 inhalations as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler forte
Description: 2 inhalations as a single dose
Study: NCT02014324

Intervention type: PROCEDURE
Intervention: Endosonography
Description: Complete endosonographic mediastinal staging is performed in 2 steps:~1. Systematic EBUS (airways)~2. Systematic EUS-B (esophagus)
Study: NCT01237756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: measurement of left and right lung ventilation
Description: Patients are ventilated after endotracheal tube placement and left and right lung ventilation if determined using electrical impedance tomography
Study: NCT03624881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter ablation with EPU
Description: Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
Study: NCT00388349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous HCT
Study: NCT01365923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: remifentanil effect site-TCI 2-4ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine with remifentanil
Description: remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
Study: NCT03178214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infacort
Description: Immediate-release multiparticulate formulation of hydrocortisone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort
Description: Immediate-release multiparticulate formulation of hydrocortisone.
Study: NCT03433079

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil gelatinase-associated lipocalin (NGAL)
Description: Blood neutrophil gelatinase-associated lipocalin (NGAL) test was performed in all patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial lactate
Description: Arterial lactate level was assessed in all patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin-6 (IL-6)
Description: The level of interleukin-6 was assessed in all patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin (PCT)
Description: The level of procalcitonin (PCT) was assessed in all patients.
Study: NCT03178214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort
Description: Immediate-release multiparticulate formulation of hydrocortisone.
Study: NCT01186263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAA for diagnostic SPECT imaging
Description: Intraarterial application of 5ml containing 500.000 particles with an activity of 150MBq.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diagnostic B20- SPECT imaging.
Description: Intraarterial application of 5ml containing 150.000 particles with an activity of 150 MBq.
Study: NCT01064063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanguard CR
Description: The Vanguard CR is a metal and polyethylene total condylar knee system. The system contains three primary components: femoral, tibial, and bearing components, and a peripheral component: the patella button.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AGC knee
Description: The AGC knee is a metal and polyethylene total condylar knee system offering complete component interchangeability.
Study: NCT01766440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 mcg/g ointment
Description: Topical ointment; twice daily application
Study: NCT04750317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib was administered at a dose 10 mg twice daily on day 1, followed by 5 mg twice daily on day 2-5. The dosage was reduced up to 5 mg once daily in patients with moderate renal impairment or moderate hepatic impairment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib was administered at a dose 10 mg twice daily on day 1, followed by 5 mg twice daily on day 2-5. The dosage was reduced up to 5 mg once daily in patients with moderate renal impairment or moderate hepatic impairment.
Study: NCT03183453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological treatment
Description: Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
Study: NCT02818309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesogaberan
Description: 120 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo